September 12, 2017 07:05 AM EDT
R&D
Pharma

Alex­ion is re­or­ga­niz­ing R&D, ax­ing 600-plus jobs and mov­ing HQ to Boston as ex­ecs prep deal spree

John Carroll

Editor & Founder

The new crew in charge of Alex­ion $ALXN is pulling up stakes from New Haven, CT and mov­ing its head­quar­ters to the big bio­phar­ma hub …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Se­nior As­traZeneca ex­ec de­tained in Chi­na amid wider in­ves­ti­ga­tion

Pfiz­er to in­vest $1B in Chi­na over next five years — re­ports

Avid Bioser­vices to be sold to pri­vate eq­ui­ty firms for $1.1B

Soft RSV sales re­veal a vac­cine mar­ket fail­ing to catch post-Covid mo­men­tum

Q&A: Demis Has­s­abis talks win­ning the No­bel Prize, build­ing an AI biotech sans lab, and Trump’s po­ten­tial im­pact

sponsored

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

A service from the Financial Times